Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Cincinnati, Ohio

Phase 3 cancer trials in Cincinnati, OH

60 Phase 3 cancer studies are recruiting participants at sites in Cincinnati as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cincinnati at a glance

Breast cancer studies recruiting in Cincinnati

Basic details from each study's public record (the 30 most recently updated of 60). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
    Registry record
    NCT06966700 · updated
  2. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    The Christ Hospital · University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT03418961 · updated
  3. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study sites
    Good Samaritan Hospital · Oncology Hematology Care, Inc.
    Registry record
    NCT05633654 · updated
  4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · The Christ Hospital
    Registry record
    NCT05879926 · updated
  5. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT06748222 · updated
  6. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020)
    Registry record
    NCT07060807 · updated
  7. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    American Society of Clinical Oncology
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06377852 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Lung cancer studies recruiting in Cincinnati

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Study site
    Clinical Study Sites
    Registry record
    NCT06767514 · updated
  2. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center ( Site 0119)
    Registry record
    NCT06623422 · updated
  3. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
    Registry record
    NCT06345729 · updated
  4. A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Oncology Hematology Care
    Registry record
    NCT06646276 · updated
  5. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06561386 · updated
  6. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Oncology_Hematology Care Clinical Trials,LLC
    Registry record
    NCT07144280 · updated
  7. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    The Christ Hospital
    Registry record
    NCT07361497 · updated
  8. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT04181060 · updated
  9. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    USO - Oncology Hematology Care
    Registry record
    NCT06119581 · updated
  10. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    UC Medical Center - Oncology
    Registry record
    NCT06452277 · updated
  11. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    The Christ Hospital Cancer Center · University of Cincinnati Medical Center
    Registry record
    NCT06712316 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Prostate cancer studies recruiting in Cincinnati

  1. A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    BioNTech SE
    Study site
    Oncology/Hematology Care, Inc.
    Registry record
    NCT07365995 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati
    Registry record
    NCT04423211 · updated
  3. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Cincinnati
    Registry record
    NCT07164443 · updated
  4. A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Cincinnati
    Registry record
    NCT07225946 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Melanoma studies recruiting in Cincinnati

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Bethesda North Hospital · Good Samaritan Hospital - Cincinnati · TriHealth Cancer Institute-Anderson
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Lymphoma studies recruiting in Cincinnati

  1. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002)
    Registry record
    NCT06717347 · updated
  2. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT05675410 · updated
  3. A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 1 and older
    • All sexes
    Sponsor
    Memorial Sloan Kettering Cancer Center
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT07223021 · updated
  4. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study sites
    Oncology Hematology Care Clinical Trials · University of Cincinnati
    Registry record
    NCT07188558 · updated
  5. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT03150693 · updated
  6. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    University of Cincinnati Cancer Center-UC Medical Center
    Registry record
    NCT07215910 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Cincinnati

  1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    University of Cincinnati Cancer Center
    Registry record
    NCT07562152 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Ask about studies near Cincinnati

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call